News


All series


All News

During a recent&nbsp;<em>Targeted Oncology&nbsp;</em>live case-based peer perspectives presentation, Corey J. Langer, MD, discussed with a group of physicians the diagnostic workup and the considerations for treatment he makes when seeing a patient with non&ndash;small cell lung cancer in the clinic. Langer, director of thoracic oncology, Abramson Cancer Center, and professor of medicine, Hematology/Oncology Division, University of Pennsylvania, reviewed treatment options based on a case study of a patient with stage III NSCLC.

In an interview with <em>Targeted Oncology</em>, Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital, talked through the current options for the treatment of patients with relapsed/refractory multiple myeloma and the clinical trial data that will shape the future of the field.

Overall survival was not improved with the use of lefitolimod as a maintenance therapy compared with local standard-of-care therapy in patients with metastatic colorectal cancer, according to early findings from the pivotal phase III IMPALA trial. The median OS was 22.0 months with lefitolimod compared with 21.9 months with standard of care, which failed to meet the primary endpoint of the trial.

Jorge Cortes, MD Cortes discussed frontline treatment options for patients with CML with <em>Targeted Oncology</em> ahead of a debate on optimal frontline regimens for chronic myeloid leukemia at the <em>3rd Annual</em> Live Medical Crossfire: Hematologic Malignancies, hosted by Physicians&rsquo; Education Resource.<br /> &nbsp;

Olaparib demonstrated a statistically significant improvement in radiographic progression-free survival compared with enzalutamide or abiraterone acetate in men with metastatic castration-resistant prostate cancer who have a homologous recombination repair mutation and have progressed on prior treatment with new hormonal anticancer treatments, according to early findings from the PROfound trial.

Next-generation sequencing has increasingly become more valuable to physicians treating cancer at academic medical centers, but these tests also need to be incorporated more into community oncology practices. A recent study, presented at the 2019 ASCO Annual Meeting, demonstrated that the use of these tests has increased in the community setting as the technology, and the use and approval of matched therapies, continues to develop.

Nivolumab demonstrated long-term survival benefit in heavily pretreated patients with advanced melanoma, renal cell carcinoma, and non&ndash;small cell lung cancer, according to an analysis of 5-year results from the CA209-003 trial. The analysis also identified favorable and adverse factors associated with survival that could inform future use of nivolumab.&nbsp;